Why This Pharma Stock Tanked Yesterday

Shares of Rigel Pharmaceuticals (Nasdaq: RIGL  ) were down big yesterday on news that AstraZeneca's (NYSE: AZN  ) oral rheumatoid arthritis drug was less effective than Abbott Labs' (NYSE: ABT  ) RA drug in clinical trials. But what does all this have to do with Rigel? In this video, Motley Fool health care analyst Brenton Flynn tells us what the connection is and why it may be a blow that will prove very difficult for Rigel to recover from.

However, what's bad for Rigel and AstraZeneca might be good news for Abbott Labs. Abbott's spinning off its pharma business early next year, and arthritis drug Humira will account for the lion's share of that company's profits. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2153165, ~/Articles/ArticleHandler.aspx, 10/25/2014 5:24:42 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement